리노바이러스 감염증 치료제 시장 보고서(2025년)

A rhinovirus infection drug is a pharmaceutical agent designed to prevent, treat, or manage infections caused by rhinoviruses, the primary cause of the common cold. These drugs work by inhibiting viral replication, blocking the virus's entry into host cells, or modulating the immune response to reduce symptom severity and shorten the infection's duration.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main products used for rhinovirus infections include antivirals, immunomodulators, vaccines, nasal sprays, and symptomatic treatments. Antiviral drugs specifically target the virus to reduce infection severity and duration, contributing to market growth driven by pharmaceutical advancements. These drugs are administered to various patient age groups, including infants, children, adults, and the elderly, using different routes such as oral, intranasal, and injectable. They are used for indications such as the common cold, asthma exacerbations, chronic obstructive pulmonary disease (COPD) exacerbations, and other related conditions. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

The rhinovirus infections drug market research report is one of a series of new reports from The Business Research Company that provides rhinovirus infections drug market statistics, including the rhinovirus infections drug global market size, regional shares, competitors with the rhinovirus infections drug market share, detailed rhinovirus infections drug market segments, market trends, and opportunities, and any further data you may need to thrive in the rhinovirus infections drug. This rhinovirus infections drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rhinovirus infections drug market size has grown strongly in recent years. It will grow from $1.26 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth observed during the historic period can be attributed to the increasing prevalence of the common cold, greater awareness about respiratory infections, rising demand for over-the-counter medications, higher healthcare expenditure, and the growing adoption of combination therapies.

The rhinovirus infections drug market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth projected during the forecast period can be attributed to rising investments in antiviral drugs, a growing demand for targeted therapies, an increasing prevalence of respiratory disorders, expanding healthcare access in emerging markets, and the rising use of biologics and monoclonal antibodies. Key trends during this period include advancements in antiviral research, progress in vaccine research, innovation in biologics and monoclonal antibodies, the development of broad-spectrum antivirals, and advancements in nanotechnology for drug delivery.

The growing prevalence of respiratory disorders is anticipated to drive the expansion of the rhinovirus infections drug market. Respiratory disorders are medical conditions that affect the lungs and airways, making breathing difficult, such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The rise in these disorders is mainly due to increased air pollution and exposure to occupational hazards, which contribute to conditions such as asthma, COPD, and pneumonia, particularly in vulnerable populations. Rhinovirus infection drugs support respiratory health by targeting viral replication, reducing inflammation, and alleviating symptoms, ultimately improving respiratory function. For example, in November 2023, the National Asthma Council of Australia reported that in 2022, Australia recorded 467 asthma-related deaths, an increase from 355 deaths in 2021. As the incidence of respiratory disorders rises, the demand for rhinovirus infections drugs continues to grow.

Leading companies in the rhinovirus infections drug market are focused on developing innovative antiviral treatments to improve treatment effectiveness, lessen symptom severity, and speed up recovery for patients. Antiviral drugs treat viral infections by inhibiting the replication of viruses within the body. These drugs are effective against a range of viruses, including influenza, HIV, hepatitis, and rhinovirus. Some antivirals prevent the virus from entering host cells, while others block viral replication or assembly. For instance, in March 2025, Altesa BioSciences Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir, an oral broad-spectrum antiviral to treat rhinovirus infections in individuals with COPD. Vapendavir works by preventing the rhinovirus from entering and replicating in human cells and has shown effectiveness against 97% of rhinoviruses and other respiratory enteroviruses. Altesa holds exclusive global rights to develop, manufacture, and commercialize vapendavir, aiming to provide targeted treatment for high-risk populations, including those with COPD and asthma.

In September 2022, RIGImmune Inc., a US-based preclinical-stage biopharmaceutical company, acquired Subintro for an undisclosed amount. This acquisition enhances RIGImmune's development of stem-loop RNA therapeutics (SLRs), designed to activate the RIG-I innate immune sensor, which may improve the treatment and prevention of viral respiratory diseases. Subintro, a UK-based biotechnology company, specializes in antiviral therapeutics targeting respiratory diseases caused by RNA viruses, such as influenza, RSV, rhinovirus, and SARS-CoV-2.

Major players in the rhinovirus infections drug market are Pfizer Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., BioFire Diagnostics LLC, hVIVO Services Limited, Romark Laboratories L.C., Cocrystal Pharma Inc., Altamira Therapeutics Ltd., Biota Pharmaceuticals Inc., Aditum Bio Management Company LLC, MetP Pharma AG, Via Nova Therapeutics Inc., Maxwell Biosciences Inc., Altesa BioSciences Inc., Apollo Therapeutics Group Limited, AIM ImmunoTech Inc., Bakar Labs, Ntvirin Pharma, bioRxiv, Pneumagen Ltd.

North America was the largest region in the rhinovirus infection drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rhinovirus infections drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rhinovirus infections drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rhinovirus infections drug market consists of sales of decongestants, antihistamines, and pain relievers and fever reducers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rhinovirus Infections Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rhinovirus infections drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rhinovirus infections drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rhinovirus infections drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Antivirals; Immunomodulators; Vaccines; Nasal Sprays; Symptomatic Treatments
• 2) By Patient Age Group: Infants; Children; Adults; Elderly
• 3) By Route Of Administration: Oral; Intranasal; Injectable
• 4) By Indication: Common Cold; Asthma Exacerbation; Chronic Obstructive Pulmonary Disease (COPD) Exacerbation; Other Indications
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
• Subsegments:
• 1) By Antivirals: Pleconaril; Vapendavir; Rupintrivir; Other Antivirals
• 2) By Immunomodulators: Interferons; Toll-Like Receptor Agonists; Other Immunomodulators
• 3) By Vaccines: Live Attenuated Vaccines; Inactivated Vaccines; Recombinant Vaccines
• 4) By Nasal Sprays: Antihistamine Nasal Sprays; Decongestant Nasal Sprays; Steroid Nasal Sprays; Saline Nasal Sprays
• 5) By Symptomatic Treatments: Analgesics; Antipyretics; Cough Suppressants; Expectorants; Antihistamines
• Companies Mentioned: Pfizer Inc.; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; BioFire Diagnostics LLC; hVIVO Services Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rhinovirus Infections Drug Market Characteristics

3. Rhinovirus Infections Drug Market Trends And Strategies

4. Rhinovirus Infections Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rhinovirus Infections Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rhinovirus Infections Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rhinovirus Infections Drug Market Growth Rate Analysis
• 5.4. Global Rhinovirus Infections Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rhinovirus Infections Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rhinovirus Infections Drug Total Addressable Market (TAM)

6. Rhinovirus Infections Drug Market Segmentation

• 6.1. Global Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antivirals
• Immunomodulators
• Vaccines
• Nasal Sprays
• Symptomatic Treatments
• 6.2. Global Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infants
• Children
• Adults
• Elderly
• 6.3. Global Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intranasal
• Injectable
• 6.4. Global Rhinovirus Infections Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Common Cold
• Asthma Exacerbation
• Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
• Other Indications
• 6.5. Global Rhinovirus Infections Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies
• 6.6. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pleconaril
• Vapendavir
• Rupintrivir
• Other Antivirals
• 6.7. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferons
• Toll-like Receptor Agonists
• Other Immunomodulators
• 6.8. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• 6.9. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Nasal Sprays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihistamine Nasal Sprays
• Decongestant Nasal Sprays
• Steroid Nasal Sprays
• Saline Nasal Sprays
• 6.10. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Symptomatic Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Antipyretics
• Cough Suppressants
• Expectorants
• Antihistamines

7. Rhinovirus Infections Drug Market Regional And Country Analysis

• 7.1. Global Rhinovirus Infections Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rhinovirus Infections Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rhinovirus Infections Drug Market

• 8.1. Asia-Pacific Rhinovirus Infections Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rhinovirus Infections Drug Market

• 9.1. China Rhinovirus Infections Drug Market Overview
• 9.2. China Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rhinovirus Infections Drug Market

• 10.1. India Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rhinovirus Infections Drug Market

• 11.1. Japan Rhinovirus Infections Drug Market Overview
• 11.2. Japan Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rhinovirus Infections Drug Market

• 12.1. Australia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rhinovirus Infections Drug Market

• 13.1. Indonesia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rhinovirus Infections Drug Market

• 14.1. South Korea Rhinovirus Infections Drug Market Overview
• 14.2. South Korea Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rhinovirus Infections Drug Market

• 15.1. Western Europe Rhinovirus Infections Drug Market Overview
• 15.2. Western Europe Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rhinovirus Infections Drug Market

• 16.1. UK Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rhinovirus Infections Drug Market

• 17.1. Germany Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rhinovirus Infections Drug Market

• 18.1. France Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rhinovirus Infections Drug Market

• 19.1. Italy Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rhinovirus Infections Drug Market

• 20.1. Spain Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rhinovirus Infections Drug Market

• 21.1. Eastern Europe Rhinovirus Infections Drug Market Overview
• 21.2. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rhinovirus Infections Drug Market

• 22.1. Russia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rhinovirus Infections Drug Market

• 23.1. North America Rhinovirus Infections Drug Market Overview
• 23.2. North America Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rhinovirus Infections Drug Market

• 24.1. USA Rhinovirus Infections Drug Market Overview
• 24.2. USA Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rhinovirus Infections Drug Market

• 25.1. Canada Rhinovirus Infections Drug Market Overview
• 25.2. Canada Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rhinovirus Infections Drug Market

• 26.1. South America Rhinovirus Infections Drug Market Overview
• 26.2. South America Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rhinovirus Infections Drug Market

• 27.1. Brazil Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rhinovirus Infections Drug Market

• 28.1. Middle East Rhinovirus Infections Drug Market Overview
• 28.2. Middle East Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rhinovirus Infections Drug Market

• 29.1. Africa Rhinovirus Infections Drug Market Overview
• 29.2. Africa Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rhinovirus Infections Drug Market Competitive Landscape And Company Profiles

• 30.1. Rhinovirus Infections Drug Market Competitive Landscape
• 30.2. Rhinovirus Infections Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioFire Diagnostics LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. hVIVO Services Limited Overview, Products and Services, Strategy and Financial Analysis

31. Rhinovirus Infections Drug Market Other Major And Innovative Companies

• 31.1. Romark Laboratories L.C.
• 31.2. Cocrystal Pharma Inc.
• 31.3. Altamira Therapeutics Ltd.
• 31.4. Biota Pharmaceuticals Inc.
• 31.5. Aditum Bio Management Company LLC
• 31.6. MetP Pharma AG
• 31.7. Via Nova Therapeutics Inc.
• 31.8. Maxwell Biosciences Inc.
• 31.9. Altesa BioSciences Inc.
• 31.10. Apollo Therapeutics Group Limited
• 31.11. AIM ImmunoTech Inc.
• 31.12. Bakar Labs
• 31.13. Ntvirin Pharma
• 31.14. bioRxiv
• 31.15. Pneumagen Ltd.

32. Global Rhinovirus Infections Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rhinovirus Infections Drug Market

34. Recent Developments In The Rhinovirus Infections Drug Market

35. Rhinovirus Infections Drug Market High Potential Countries, Segments and Strategies

• 35.1 Rhinovirus Infections Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rhinovirus Infections Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rhinovirus Infections Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34955_Rhinovirus_Infections_Drug_GMR_2025